货号:A226220
同义名:
ITMN-191; R7227
Danoprevir, a peptidomimetic, is an inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2 nM - 3.5 nM.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
靶点 |
|
描述 | The NS3 protein is a chymotrypsin-like serine protease that is activated by association with NS4A. NS3/4A (nonstructural protein 3/4A) liberates the functional form of the viral polymerase and other viral proteins required for HCV replication. Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease of HCV with an IC50 rang of 0.2 - 3.5 nM. In peptide cleavage assays, danoprevir reduced genotype 1b NS3/4A protease activity in a concentration-dependent fashion. Dose-dependent reductions of a patient-derived HCV genotype 1b replicon harbored in hepatocyte-derived Huh7 cells were observed following 2-day incubation with danoprevir. In any case, treatment with 45 nM danoprevir (3 times its EC90) reduced HCV replicon RNA levels below the RT-PCR detection limit in a sustained fashion and completely cleared replicon RNA. In monkey liver tissue, the maximum concentration in the liver (Cmax) and the 12-h-postdose concentration in the liver (C12 h) were sufficient to reduce HCV replicon RNA by 3.1 log10 and 2.0 log10 units, respectively[3]. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.37mL 0.27mL 0.14mL |
6.83mL 1.37mL 0.68mL |
13.66mL 2.73mL 1.37mL |
CAS号 | 850876-88-9 |
分子式 | C35H46FN5O9S |
分子量 | 731.83 |
SMILES Code | O=C(N1CC2=C(C(F)=CC=C2)C1)O[C@@H](C3)C[C@](C(N[C@@](C4)(C(NS(=O)(C5CC5)=O)=O)[C@]4([H])/C=C\CCCCC[C@@H]6NC(OC(C)(C)C)=O)=O)([H])N3C6=O |
MDL No. | MFCD16038038 |
别名 | ITMN-191; R7227; RG7227; RO5190591 |
运输 | 蓝冰 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Sealed in dry, 2-8°C |
溶解方案 |
请根据您的动物给药指南选择适当的溶解方案。 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|